Li Wenhui, Li Wenhan, Xu Zhen
Internal Medicine Department II, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, 266042, China.
Department of Geriatrics, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China.
Discov Oncol. 2025 Jun 10;16(1):1050. doi: 10.1007/s12672-025-02896-3.
Lung cancer ranks among the foremost causes of mortality associated with cancer. Non-small cell lung cancer (NSCLC) represents the predominant subtype, and the survival rate is suboptimal.
This study investigated the clinical relationship between MIR99AHG and NSCLC, as well as elucidated the potential mechanisms. This study identified novel molecular targets for NSCLC.
This study involved 119 NSCLC patients and 105 benign lung lesions patients. qPCR was employed to assess the expression of MIR99AHG and miR-194-5p. The clinical correlation, diagnostic value, and predictive capacity of MIR99AHG were evaluated utilizing chi-square tests, ROC analysis, and logistic regression models, respectively. A cell model exhibiting overexpression of MIR99AHG was established, and the impact of MIR99AHG overexpression, and in conjunction with miR-194-5p overexpression, on the functional characteristics of lung cancer cells was investigated through CCK-8 and Transwell assays.
MIR99AHG exhibited down-regulation in NSCLC patients' serum and lung cancer cell lines, while miR-194-5p showed up-regulation. The expression of MIR99AHG was correlated with TNM staging and LNM status in early-stage NSCLC patients. MIR99AHG demonstrated predictive capabilities for the early NSCLC occurrence, both independently and in conjunction with serum tumor markers, and exhibited significant diagnostic potential for this condition. Moreover, the overexpression of MIR99AHG could inhibit the proliferation, migration, and invasion of lung cancer cells. However, the concurrent overexpression of MIR99AHG and miR-194-5p appeared to negate this inhibitory effect.
MIR99AHG might as a supplementary diagnosis tool for early NSCLC. Furthermore, MIR99AHG could regulate the initiation and advancement of NSCLC via miR-194-5p.
肺癌是癌症相关死亡的主要原因之一。非小细胞肺癌(NSCLC)是主要的亚型,其生存率并不理想。
本研究调查了MIR99AHG与NSCLC之间的临床关系,并阐明了潜在机制。本研究确定了NSCLC的新分子靶点。
本研究纳入了119例NSCLC患者和105例良性肺病变患者。采用qPCR评估MIR99AHG和miR-194-5p的表达。分别利用卡方检验、ROC分析和逻辑回归模型评估MIR99AHG的临床相关性、诊断价值和预测能力。建立了MIR99AHG过表达的细胞模型,并通过CCK-8和Transwell实验研究MIR99AHG过表达以及与miR-194-5p过表达联合对肺癌细胞功能特性的影响。
MIR99AHG在NSCLC患者血清和肺癌细胞系中表达下调,而miR-194-5p表达上调。MIR99AHG的表达与早期NSCLC患者的TNM分期和LNM状态相关。MIR99AHG对早期NSCLC的发生具有独立的预测能力,并与血清肿瘤标志物联合使用时也具有显著的诊断潜力。此外,MIR99AHG过表达可抑制肺癌细胞的增殖、迁移和侵袭。然而,MIR99AHG和miR-194-5p的同时过表达似乎抵消了这种抑制作用。
MIR99AHG可能作为早期NSCLC的辅助诊断工具。此外,MIR99AHG可通过miR-194-5p调节NSCLC的发生和发展。